(COR) Cencora - Overview
Stock: Pharmaceuticals, Distribution, Logistics, Wholesale
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.78% |
| Yield on Cost 5y | 2.19% |
| Yield CAGR 5y | 6.03% |
| Payout Consistency | 90.0% |
| Payout Ratio | 14.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 25.8% |
| Relative Tail Risk | -8.96% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.54 |
| Alpha | 39.15 |
| Character TTM | |
|---|---|
| Beta | -0.027 |
| Beta Downside | -0.221 |
| Drawdowns 3y | |
|---|---|
| Max DD | 11.95% |
| CAGR/Max DD | 2.73 |
Description: COR Cencora January 27, 2026
Cencora Inc. (NYSE: COR) is a global pharmaceutical-distribution and services company that operates two main segments. The U.S. Healthcare Solutions segment supplies generic and injectable drugs, OTC products, home-health equipment, plasma, vaccines, and specialty pharmaceuticals to a broad customer base that includes hospitals, retail and mail-order pharmacies, long-term-care facilities, and specialty clinics. It also offers ancillary services such as pharmacy-management consulting, supply-chain software, packaging, clinical-trial support, data-analytics, and veterinary-product distribution. The International Healthcare Solutions segment provides wholesale distribution, global commercialization, and specialty logistics for biopharma products to pharmacies, doctors, and hospitals worldwide.
In its most recent fiscal year (2023), Cencora reported revenue of $ $71.5 billion, a 4.2 % YoY increase driven largely by higher specialty-drug volumes and expanded logistics contracts. Adjusted EBITDA margin stood at 5.9 %, up from 5.3 % in 2022, reflecting modest operating leverage. The company generated $ 2.1 billion of free cash flow, enabling a $ 1.5 billion share-repurchase program announced in Q4 2023. As of December 2024, Cencora held roughly 14 % market share of the U.S. pharmaceutical-distribution market, according to IQVIA data, positioning it as the second-largest distributor after McKesson.
Key drivers of Cencora’s outlook include the continued growth of specialty-drug spend (projected to rise at a 9 % CAGR through 2028), an aging U.S. population that expands demand for chronic-care and injectable therapies, and persistent supply-chain constraints that increase the value of integrated logistics and temperature-controlled transport services. Conversely, margin pressure could arise from tighter reimbursement rates and the ongoing consolidation of pharmacy benefit managers, which may compress distribution fees.
For a deeper, data-driven assessment of how these factors translate into valuation risk and upside, a quick look at ValueRay’s analyst toolkit can be a useful next step.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 1.63b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 5.53 > 1.0 |
| NWC/Revenue: -1.53% < 20% (prev -1.49%; Δ -0.04% < -1%) |
| CFO/TA 0.05 > 3% & CFO 4.29b > Net Income 1.63b |
| Net Debt (6.17b) to EBITDA (3.82b): 1.62 < 3 |
| Current Ratio: 0.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (195.3m) vs 12m ago 0.07% < -2% |
| Gross Margin: 3.36% > 18% (prev 0.03%; Δ 333.2% > 0.5%) |
| Asset Turnover: 442.0% > 50% (prev 439.1%; Δ 2.92% > 0%) |
| Interest Coverage Ratio: 6.44 > 6 (EBITDA TTM 3.82b / Interest Expense TTM 431.0m) |
Altman Z'' 0.21
| A: -0.06 (Total Current Assets 54.15b - Total Current Liabilities 59.13b) / Total Assets 78.36b |
| B: 0.09 (Retained Earnings 6.97b / Total Assets 78.36b) |
| C: 0.04 (EBIT TTM 2.78b / Avg Total Assets 73.71b) |
| D: 0.08 (Book Value of Equity 6.07b / Total Liabilities 76.27b) |
| Altman-Z'' Score: 0.21 = B |
Beneish M -3.07
| DSRI: 0.99 (Receivables 25.98b/24.55b, Revenue 325.78b/303.19b) |
| GMI: 0.86 (GM 3.36% / 2.89%) |
| AQI: 1.13 (AQ_t 0.28 / AQ_t-1 0.25) |
| SGI: 1.07 (Revenue 325.78b / 303.19b) |
| TATA: -0.03 (NI 1.63b - CFO 4.29b) / TA 78.36b) |
| Beneish M-Score: -3.07 (Cap -4..+1) = AA |
What is the price of COR shares?
Over the past week, the price has changed by +0.01%, over one month by +3.78%, over three months by -0.11% and over the past year by +47.09%.
Is COR a buy, sell or hold?
- StrongBuy: 10
- Buy: 1
- Hold: 5
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the COR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 399.8 | 11.3% |
| Analysts Target Price | 399.8 | 11.3% |
| ValueRay Target Price | 484.9 | 35% |
COR Fundamental Data Overview February 07, 2026
P/E Forward = 20.0
P/S = 0.2103
P/B = 35.8984
P/EG = 0.8364
Revenue TTM = 325.78b USD
EBIT TTM = 2.78b USD
EBITDA TTM = 3.82b USD
Long Term Debt = 7.54b USD (from longTermDebt, last fiscal year)
Short Term Debt = 342.3m USD (from shortTermDebt, last quarter)
Debt = 7.92b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.17b USD (from netDebt column, last quarter)
Enterprise Value = 74.67b USD (68.51b + Debt 7.92b - CCE 1.75b)
Interest Coverage Ratio = 6.44 (Ebit TTM 2.78b / Interest Expense TTM 431.0m)
EV/FCF = 20.70x (Enterprise Value 74.67b / FCF TTM 3.61b)
FCF Yield = 4.83% (FCF TTM 3.61b / Enterprise Value 74.67b)
FCF Margin = 1.11% (FCF TTM 3.61b / Revenue TTM 325.78b)
Net Margin = 0.50% (Net Income TTM 1.63b / Revenue TTM 325.78b)
Gross Margin = 3.36% ((Revenue TTM 325.78b - Cost of Revenue TTM 314.83b) / Revenue TTM)
Gross Margin QoQ = 3.58% (prev 3.11%)
Tobins Q-Ratio = 0.95 (Enterprise Value 74.67b / Total Assets 78.36b)
Interest Expense / Debt = 0.91% (Interest Expense 72.4m / Debt 7.92b)
Taxrate = 20.11% (142.5m / 708.6m)
NOPAT = 2.22b (EBIT 2.78b * (1 - 20.11%))
Current Ratio = 0.92 (Total Current Assets 54.15b / Total Current Liabilities 59.13b)
Debt / Equity = 4.15 (Debt 7.92b / totalStockholderEquity, last quarter 1.91b)
Debt / EBITDA = 1.62 (Net Debt 6.17b / EBITDA 3.82b)
Debt / FCF = 1.71 (Net Debt 6.17b / FCF TTM 3.61b)
Total Stockholder Equity = 1.60b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.20% (Net Income 1.63b / Total Assets 78.36b)
RoE = 101.4% (Net Income TTM 1.63b / Total Stockholder Equity 1.60b)
RoCE = 30.37% (EBIT 2.78b / Capital Employed (Equity 1.60b + L.T.Debt 7.54b))
RoIC = 23.56% (NOPAT 2.22b / Invested Capital 9.42b)
WACC = 5.29% (E(68.51b)/V(76.43b) * Re(5.82%) + D(7.92b)/V(76.43b) * Rd(0.91%) * (1-Tc(0.20)))
Discount Rate = 5.82% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -1.63%
[DCF Debug] Terminal Value 86.12% ; FCFF base≈3.61b ; Y1≈3.53b ; Y5≈3.58b
Fair Price DCF = 518.8 (EV 107.09b - Net Debt 6.17b = Equity 100.92b / Shares 194.5m; r=5.90% [WACC]; 5y FCF grow -3.10% → 2.90% )
EPS Correlation: 61.47 | EPS CAGR: -3.02% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.58 | Revenue CAGR: 11.20% | SUE: -0.13 | # QB: 0
EPS next Quarter (2026-03-31): EPS=4.87 | Chg30d=-0.039 | Revisions Net=-1 | Analysts=13
EPS current Year (2026-09-30): EPS=17.63 | Chg30d=-0.006 | Revisions Net=+1 | Growth EPS=+10.2% | Growth Revenue=+7.2%
EPS next Year (2027-09-30): EPS=19.60 | Chg30d=+0.097 | Revisions Net=+1 | Growth EPS=+11.2% | Growth Revenue=+6.3%